The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals

References

• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. WHO Press, Geneva, Switzerland (2006).
   Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA300(5), 555–570 (2008).
   PubMed Web of Science ®Google Scholar
• Isentress (raltegravir), package insert. Merck (2009).
   Google Scholar
• Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin. Ther.30(10), 1747–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med.359(4), 339–353 (2008).
   PubMed Web of Science ®Google Scholar
• Lennox J, Dejesus E, Lazzarin A et al. Subgroup analyses from STARTMRK, a Phase III Study of raltegravir-based vs efavirenz-based combination therapy in treatment-naive HIV-infected patients. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8–11 February 2009.
   Google Scholar
• Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab.76(6), 1423–1427 (1993).
   PubMed Web of Science ®Google Scholar
• Hellerstein MK, Grunfeld C, Wu K et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J. Clin. Endocrinol. Metab.76(3), 559–565 (1993).
   PubMedGoogle Scholar
• Llibre JM, Domingo P, Palacios R et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS20(10), 1407–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis.37(5), 613–627 (2003).
   PubMed Web of Science ®Google Scholar
• Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation104(3), 257–262 (2001).
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation100(7), 700–705 (1999).
   PubMed Web of Science ®Google Scholar
• Tebas P, Zhang J, Yarasheski K et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J. Acquir. Immune. Defic. Syndr.45(2), 193–200 (2007).
   PubMed Web of Science ®Google Scholar
• Soriano V, Garcia-Gasco P, Vispo E et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J. Antimicrob. Chemother.61(1), 200–205 (2008).
   PubMed Web of Science ®Google Scholar
• Wensing AM, Reedijk M, Richter C, Boucher CA, Borleffs JC. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS15(16), 2191–2193 (2001).
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS17(8), 1179–1193 (2003).
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med.356(17), 1723–1735 (2007).
   PubMed Web of Science ®Google Scholar
• Eron J, Andrade J, Zajdenverg R et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8–11 February 2009 (Abstract 70aLB).
   Google Scholar
• Talbot A, Machouf N, Thomas R et al. Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal Cohort. Presented at: XVII International AIDS Conference. Mexico City, Mexico, 3–8 August 2008.
   Google Scholar
• De Castro N, Braun J, Charreau I et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin. Infect. Dis.49(8), 1259–1267 (2009).
   PubMed Web of Science ®Google Scholar
• Masquelier B, Breilh D, Neau D et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir–ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother.46(9), 2926–2932 (2002).
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Isaacson JD, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol.75(16), 7462–7469 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell J et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med.359(4), 355–365 (2008).
   PubMed Web of Science ®Google Scholar